Enanta Pharmaceuticals Inc
NASDAQ:ENTA
Intrinsic Value
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. [ Read More ]
The intrinsic value of one
ENTA
stock under the Base Case scenario is
31.04
USD.
Compared to the current market price of 12.99 USD,
Enanta Pharmaceuticals Inc
is
Undervalued by 58%.
Enanta Pharmaceuticals Inc's market capitalization is 274.8m USD.
ENTA stock price is 12.99 USD.
ENTA stock price (12.99 USD) is 58% less than its Intrinsic Value (31.04 USD).
ENTA. Open DCF Valuation
ENTA stock price (12.99 USD) is 58% less than its Relative Value (31.04 USD). Open Relative Valuation
ENTA has upside potential of 75% compared to the average analyst price target.
Open Wall St Estimates
ENTA's Revenue is forecast to fall at a rate of 1% per year over the next 3 years.
ENTA's Revenue has dropped by 10% over the past 12 months.
ENTA's Revenue has been falling by 10% per year for the last 3 years.
ENTA's long-term assets (428m USD) exceed its long-term liabilties (237m USD).
ENTA's ROE (Return on Equity) has significantly decreased in the last 3 years from -16% to -56%, and is approaching profitability.
ENTA's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -65% to -137%, and is approaching profitability.
ENTA has negative Operating Income for the last twelve months.
ENTA has negative Net Income for the last twelve months.
ENTA's ROE (Return on Equity) for the past 12 months is negative and is equal to -56%.
ENTA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -137%.
ENTA has negative Free Cash Flow for the last twelve months.
ENTA's D/E (Debt to Equity) is very low and is equal to 0.01.
ENTA has negative three-year average ROE (Return on Equity): -32%. The company is not efficient at transforming stockholders' equity into net income.
ENTA has negative three-year average ROIC (Return on Invested Capital): -90%. The company is not efficient at using invested capital to generate operating income.
ENTA's short-term assets (390m USD) exceed its short-term liabilties (62m USD).
ENTA has negative Net Debt. This means that the company has more cash and short-term investments (337m USD) than debt (1m USD).
ENTA's Altman Z-Score is very low and is equal to -1.23.
Valuation Backtest
Enanta Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
ENTA
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Enanta Pharmaceuticals Inc
Balance Sheet Decomposition
Enanta Pharmaceuticals Inc
| Current Assets | 390.3m |
| Cash & Short-Term Investments | 337.2m |
| Receivables | 39.9m |
| Other Current Assets | 13.2m |
| Non-Current Assets | 38.2m |
| PP&E | 33.5m |
| Other Non-Current Assets | 4.7m |
| Current Liabilities | 62.4m |
| Accounts Payable | 9.3m |
| Accrued Liabilities | 16.6m |
| Other Current Liabilities | 36.5m |
| Non-Current Liabilities | 174.2m |
| Long-Term Debt | 1.4m |
| Other Non-Current Liabilities | 172.8m |
Earnings Waterfall
Enanta Pharmaceuticals Inc
|
Revenue
|
73.6m
USD
|
|
Operating Expenses
|
-215.7m
USD
|
|
Operating Income
|
-142.1m
USD
|
|
Other Expenses
|
3.8m
USD
|
|
Net Income
|
-138.2m
USD
|
Free Cash Flow Analysis
Enanta Pharmaceuticals Inc
ENTA Profitability Score
Profitability Due Diligence
Enanta Pharmaceuticals Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
Score
Enanta Pharmaceuticals Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
ENTA Solvency Score
Solvency Due Diligence
Enanta Pharmaceuticals Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Score
Enanta Pharmaceuticals Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ENTA Price Targets Summary
Enanta Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
ENTA
is 22.73 USD
with a low forecast of 13.13 USD and a high forecast of 36.75 USD.
Ownership
ENTA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ENTA Price
Enanta Pharmaceuticals Inc
| Average Annual Return | -5.82% |
| Standard Deviation of Annual Returns | 54.7% |
| Max Drawdown | -92% |
| Market Capitalization | 274.8m USD |
| Shares Outstanding | 21 160 000 |
| Percentage of Shares Shorted | 13.79% |
Company Profile
Enanta Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in development of small molecule drugs for the treatment of viral infections and liver diseases. The firm has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). The firm has discovered glecaprevir, a protease inhibitor discovered and developed for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET. Its product candidates also include EDP-514, EDP-305 and EDP-938. The firm's subsidiary is Enanta Pharmaceuticals Security Corporation.
Contact
IPO
Employees
Officers
The intrinsic value of one
ENTA
stock under the Base Case scenario is
31.04
USD.
Compared to the current market price of 12.99 USD,
Enanta Pharmaceuticals Inc
is
Undervalued by 58%.
You don't have any saved screeners yet
